Skip to main content
Equibles

NVS · Novartis AG

Track NVS — free

Use NVS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NVS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$143.24 -2.47 (-1.70%)
Rebalance outlook locked
Market Cap
$276.48B
Shares
1.90B
Volume · Sep 30 2.26M Avg daily vol (3M) 1.93M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$145.71 Open$144.81 Day$144.46–146.18 52W close$121.80–168.62 Avg vol 30d2.2M Short int5.2M · 0.3% float · 1.5d Short vol42% Last earningsDec 31, 2025 DataJan 2020–Sep 2026

Up next

Q4 2025 earnings call transcript
call held Dec 31, 2025

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+8.4%
Year over year
Operating margin
32.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$11.59B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-3.4%
Year over year · fewer shares
Price change (1Y)
+17.4%
Trailing year
Short interest
0.3%
Latest settlement · 1.5 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Weak Sentiment Bullish Fundamentals Limited Quant / Vol Moderate
Market backdrop VIX 16 · calm Equity put/call 0.38
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg −3%
below
Price vs 50-day avg −4%
below
RSI (14) 48
neutral
MACD trend Positive
52-week position 51%
mid-range
Momentum
relative strength
Weak
1-month return −4%
trailing
6-month return −6%
trailing
YTD return +6%
this year
Relative strength −19%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $151 › 200d $151 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +133 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.27% of float · ▼ -7.6% MoM · 1.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
1,639 holders — near 3-yr high, broad support
Squeeze score 32
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Moderate
Volatility 27%
annualized · 1-yr
Max drawdown −19%
past year
ATR 2.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Sep 30, 2025
pre-taxane launch
Peak sales at least $3B
HSPC launch
Peak sales at least $5B
Prior guidance period ended · from the Earnings Call filed Sep 30, 2025
Core net financial expenses · full year 2025 $1.1B

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−3% Neutral
Price vs 50-day avg
−4% Neutral
RSI (14)
48 Neutral
MACD trend
Positive Bullish
52-week position
51% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $151 › 200d $151 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +133 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.27% of float · ▼ -7.6% MoM · 1.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
1,639 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $122 Now $146 · 51% Range high $169
vs 200-day avg -3% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - General — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NVS
Novartis AG
this stock
$276.48B +5.7% — — 0.3%
LLY
ELI LILLY & Co
 $1.11T +10.2% +44.7% 39.7 0.8%
JNJ
Johnson & Johnson
 $653.61B +29.3% +6.0% 31.5 0.9%
ABBV
AbbVie Inc.
 $466.80B +15.2% +8.6% 74.6 1.1%
MRK
Merck & Co., Inc.
 $367.07B +41.8% +1.3% 119.0 1.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
1,639
% held
7.5%
Net QoQ
-6.9M sh
Top holder
Fisher Asset Management,…
Held Float
View
Held by Funds
Fund positions
167
View
Short & Settlement
Short Interest Falling
Shares short
5.2M
Days to cover
1.5d
Change
-429.4K sh
View
Short Volume
Short vol %
42%
As of
Sep 29, 2026
Short Total
View
Fails to Deliver
FTD shares
41.5K
Value
$5.7M
As of
Sep 10, 2026
View
Off-Exchange
Off-exchange %
36.9%
Week of
Aug 24, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Lisa McClain
Amount
$1.0K–$15.0K
Traded
Oct 31, 2025
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 8, 2026
This year
10
View
Proposed Sales
Value
$1.0M
Shares
6.8K
Filed
Apr 30, 2026
View
Earnings & Events
Earnings Calls
Last call
Dec 31, 2025
View

Performance

5D 20D 120D MTD YTD
NVS +3.1% -4.2% -5.6% -4.2% +5.7%
SPY -1.2% -0.4% +13.1% -0.4% +12.1%
vs SPY +4.3% -3.8% -18.7% -3.8% -6.4%
Key facts CIK 1114448 CUSIP 66987V109 13F (30d) 36 filings 20 filers Visit website Investor relations